Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SHPH Shuttle Pharmaceuticals Inc

Trading 06-26 14:50:03 EDT

0.3883

+0.0073

+1.92%

High0.3950	Low0.3700	Vol68.17K
Open0.3710	D1 Closing0.3810	Amplitude6.56%
Mkt Cap6.53M	Tradable Cap3.85M	Total Shares16.82M
T/O25.69K	T/O Rate0.69%	Tradable Shares9.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SHPH","market":"US","secType":"STK","nameCN":"Shuttle Pharmaceuticals Inc","latestPrice":0.3883,"timestamp":1719427146560,"preClose":0.381,"halted":0,"volume":68165,"delay":0,"floatShares":9927021,"shares":16819893,"eps":-0.469454,"marketStatus":"Trading","change":0.0073,"latestTime":"06-26 14:50:03 EDT","open":0.371,"high":0.395,"low":0.37,"amount":25690.6850372,"amplitude":0.065617,"askPrice":0.394,"askSize":400,"bidPrice":0.38,"bidSize":1070,"shortable":3,"etf":0,"ttmEps":-0.469454,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1719432000000},"marketStatusCode":2,"adr":0,"listingDate":1661918400000,"exchange":"NASDAQ","adjPreClose":0.381,"preHourTrading":{"tag":"盘前","latestPrice":0.3652,"preClose":0.381,"latestTime":"08:30 EDT","volume":7906,"amount":2886.9913276,"timestamp":1719405016310},"postHourTrading":{"tag":"盘后","latestPrice":0.3949,"preClose":0.393,"latestTime":"19:04 EDT","volume":366,"amount":144.2152,"timestamp":1719356677403},"volumeRatio":1.889512},"requestUrl":"/m/hq/s/SHPH/tweets","defaultTab":"tweets","newsList":[{"id":"2444430831","title":"Shuttle Pharmaceuticals Names Timothy Lorber as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2444430831","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444430831?lang=en_us&edition=fundamental","pubTime":"2024-06-19 00:01","pubTimestamp":1718726461,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings  said Tuesday it has appointed Timothy Lorber as chief financial officer, succeeding Michael Vander Hoek, who will assume the role of vice president of regulatory on a full-time basis.Lorber will initially serve as part-time CFO through Sept. 9, and become full-time CFO starting Sept. 10, the company said.Lorber more recently served in leadership roles with several privately held businesses, Shuttle Pharmaceuticals said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2444436985","title":"Shuttle Pharmaceuticals Welcomes New CFO Timothy Lorber","url":"https://stock-news.laohu8.com/highlight/detail?id=2444436985","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444436985?lang=en_us&edition=fundamental","pubTime":"2024-06-18 21:58","pubTimestamp":1718719130,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has provided an update. Shuttle Pharmaceuticals Holdings, Inc. has appointed seasoned finance profess...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shuttle-pharmaceuticals-welcomes-new-cfo-timothy-lorber?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shuttle-pharmaceuticals-welcomes-new-cfo-timothy-lorber?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2444647433","title":"BRIEF-Shuttle Pharma Appoints Timothy Lorber As Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2444647433","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444647433?lang=en_us&edition=fundamental","pubTime":"2024-06-18 21:43","pubTimestamp":1718718194,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc   :   * SHUTTLE PHARMA APPOINTS TIMOTHY LORBER AS CHIEF FINANCIAL OFFICER   * SHUTTLE PHARMACEUTICALS: MICHAEL VANDER HOEK WILL BE TRANSITIONING OUT OF HIS ROLE AS CHIEF FINANCIAL OFFICERSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2444435827","title":"Shuttle Pharma names Timothy Lorber as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2444435827","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444435827?lang=en_us&edition=fundamental","pubTime":"2024-06-18 21:22","pubTimestamp":1718716922,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (NASDAQ:SHPH) announced on Tuesday that Timothy Lorber will take over as CFO from Michael Vander Hoek.\nLorber will initially serve as the company's part-time CFO until September 9, and, effective September 10, 2024, he will assume the role of full-time CFO.\nPress release.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4116956-shuttle-pharma-names-timothy-lorber-as-cfo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QLD","PSQ","TQQQ","SQQQ","NQmain",".IXIC","SHPH","QID","BK4139","MNQmain","QQQ"],"gpt_icon":0},{"id":"2444848744","title":"Press Release: Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2444848744","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444848744?lang=en_us&edition=fundamental","pubTime":"2024-06-18 21:00","pubTimestamp":1718715600,"startTime":"0","endTime":"0","summary":"Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory. GAITHERSBURG, Md., June 18, 2024  -- Shuttle Pharmaceuticals Holdings, Inc.  , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy , today announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer. The Company's current Chief Financial Officer, Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis.\"Michael Vander Hoek has been performing two critical roles for Shuttle for the past four years as both our Chief Financial Officer and our Vice President of Regulatory. With the Company's growth and the planned initiation of the multi-center Phase 2 clinical trial, Michael will focus his efforts on the successful execution o","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2437547245","title":"Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2437547245","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437547245?lang=en_us&edition=fundamental","pubTime":"2024-05-23 04:15","pubTimestamp":1716408900,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., May 22, 2024  -- Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy , today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.Dr. Dritschilo’s presentation will include an update on the Company's progress toward clinical and scientific milestones of its Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients with glioblastoma, a deadly malignancy of the brain with no known cure. Additionally, he will provide an update on the Company’s plans of its subsidiary, Shuttle Diagnostics, Inc., to develop predictive biomarkers for prostate cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharma-participate-lytham-partners-201500421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2435146285","title":"Shuttle Pharmaceuticals reports Q1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2435146285","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435146285?lang=en_us&edition=fundamental","pubTime":"2024-05-14 22:16","pubTimestamp":1715696164,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals press release  (NASDAQ:SHPH): At March 31, 2024, Shuttle Pharma’s cash balance was approximately $4.2 million (including cash, cash equivalents and marketable securities).","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105854-shuttle-pharmaceuticals-reports-q1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QID","MNQmain",".IXIC","PSQ","NQmain","BK4139","QQQ","QLD","SHPH","SQQQ","TQQQ"],"gpt_icon":0},{"id":"2435551537","title":"Shuttle Pharmaceuticals Q1 EPS $(0.10) Down From $(0.07) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2435551537","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435551537?lang=en_us&edition=fundamental","pubTime":"2024-05-14 21:11","pubTimestamp":1715692288,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.10) per share. This is a 42.86 percent decrease over losses of $(0.07) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38816457/shuttle-pharmaceuticals-q1-eps-0-10-down-from-0-07-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH"],"gpt_icon":0},{"id":"2435515888","title":"Press Release: Shuttle Pharma Provides First Quarter 2024 Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435515888","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435515888?lang=en_us&edition=fundamental","pubTime":"2024-05-14 21:00","pubTimestamp":1715691600,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., May 14, 2024  -- Shuttle Pharmaceuticals Holdings, Inc.  , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy , today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024.-- Received FDA approval to proceed with the Phase 2 Clinical Trial of. Ropidoxuridine for treatment of patients with glioblastoma, a deadly. malignancy of the brain with no known cure.-- Received central institutional review board  approval for the. Phase 2 clinical trial. For multicenter studies, the central IRB is the. IRB that conducts reviews on behalf of all study sites that agree to. participate in the centralized review process. For sites at institutions. that have an IRB that would ordinarily review research conducted at the. site, the central IRB should reach agreement with each individual. IRBs about how to ap","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2431857978","title":"Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV","url":"https://stock-news.laohu8.com/highlight/detail?id=2431857978","media":"ACCESSWIRE","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431857978?lang=en_us&edition=fundamental","pubTime":"2024-04-29 21:00","pubTimestamp":1714395600,"startTime":"0","endTime":"0","summary":"LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las Vegas, NV.The Planet MicroCap Showcase begins on Tuesday, April 30, 2024 with the \"MicroCap Investing Workshop\" starting at 12:00pm PST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders, followed by 96 MicroCap public and private company presentations on Wednesday, May 1, 2024, and 1x1 meetings on Thursday, May 2, 2024.On Wednesday, May 1, 2024, the following issuers will be presenting their companies. Below are the webcasting links to view those presentations if you can't attend the showcase live.Altigen Communications - \"Top Tier Track\" Q&A with Maj Soueidan, GeoInvesting.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keynotes-educational-panels-96-companies-130000391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FWBI","SHPH","BENF","YERBF","DMGGF","ACHV","HGBL","NXGLW","APCX","VOXR","INXSF","ADMQ","GLGI","PRPH","NAOV","LRHC","QPRC","NEPH","LUXHP","DDOSF","CING","BYRN","CREX","ALCO","CXDO","FTHM","SPGC","DCMDF","LAKE","PAPL","XELB","LUXH","PERF","BSEM","COCH","SABOF","UGEIF","VCIG","CYCA","HWAIF","LGVN","DLPN","GREE","MTC","RAIL","ACON","TGCB","NXGL","TRUG","WISA","XXII","TNXP","ATOS","RELL","SSKN","GLXZ"],"gpt_icon":0},{"id":"2429142747","title":"Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2429142747","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429142747?lang=en_us&edition=fundamental","pubTime":"2024-04-24 04:15","pubTimestamp":1713903300,"startTime":"0","endTime":"0","summary":"Dr. Dritschilo’s presentation will include an update on the Company's progress toward clinical and scientific milestones of its Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients with glioblastoma, a deadly malignancy of the brain with no known cure. Additionally, he will provide an update on the Company’s plans of its subsidiary, Shuttle Diagnostics, Inc., to develop predictive biomarkers for prostate cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications.Conference Location: Paris Hotel & Casino in Las Vegas, NV. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may relate to statements concerning future results, strategy and plans of the Company (including certain statements which may be identified by","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharmaceuticals-present-planet-microcap-201500725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2425512927","title":"Shuttle Pharmaceuticals files to sell subscription rights to buy $4.5M in units","url":"https://stock-news.laohu8.com/highlight/detail?id=2425512927","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2425512927?lang=en_us&edition=fundamental","pubTime":"2024-04-06 05:27","pubTimestamp":1712352448,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (NASDAQ:SHPH) files a prospectus to sell subscription rights to buy $4.5M in units.\nThis prospectus is not an offer to sell these securities.\nSEC Filing\n\n\nMore on Shuttle Pharmaceuticals  Financial information for Shuttle Pharmaceuticals","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087699-shuttle-pharmaceuticals-files-to-sell-subscription-rights-to-buy-45m-in-units","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","QLD","PSQ","NQmain","TQQQ","QQQ","SHPH","SQQQ","MNQmain",".IXIC","QID"],"gpt_icon":0},{"id":"2424848254","title":"Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2424848254","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424848254?lang=en_us&edition=fundamental","pubTime":"2024-04-03 21:00","pubTimestamp":1712149200,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., April 03, 2024  -- Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy , today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference.Dr. Dritschilo’s presentation will be on Thursday, April 4, 2024 at 3:10pm ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.During the event, Dr. Dritschilo will also update participants on plans for subsidiary Shuttle Diagnostics, Inc. to enable its development of recently licensed intellectual properties for predictive biomarkers for prostate cancer outcomes following radiation therapy and for a novel PSMA ligand for theranostic applications, developmental progress made since his last presentation to participants at the Emerging Growth Conference in Marc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharmaceuticals-present-emerging-growth-130000577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2424097239","title":"Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2424097239","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424097239?lang=en_us&edition=fundamental","pubTime":"2024-04-02 19:00","pubTimestamp":1712055600,"startTime":"0","endTime":"0","summary":"MIAMI, April 02, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-69-110000672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACOGF","GOEV","BK4211","CLRD","DRMA","CIA","CREV","IPWR","BK4139","MNQmain","LDTC","BK4096","ANPCY","ASPI","BK4082","QLD","OPHC",".IXIC","SHPH","BK4196","QQQ","BK4023","GCTK","NQmain","PSQ","FDXTF","BK4099","BK4007","SQQQ","BIXT","MYRUF","BK4162","BK4539","QID","GOEVW","SNES","CRVO","TQQQ","DRMAW","AYTU","BK4124"],"gpt_icon":0},{"id":"2421815876","title":"Shuttle Pharmaceuticals Q4 EPS $(0.11) Down From $(0.06) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2421815876","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2421815876?lang=en_us&edition=fundamental","pubTime":"2024-03-22 21:00","pubTimestamp":1711112458,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.11) per share. This is a 83.33 percent decrease over losses of $(0.06) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37890405/shuttle-pharmaceuticals-q4-eps-0-11-down-from-0-06-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH"],"gpt_icon":0},{"id":"2421815446","title":"Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2421815446","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2421815446?lang=en_us&edition=fundamental","pubTime":"2024-03-22 21:00","pubTimestamp":1711112400,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., March 21, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc.  , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy , today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023.Created Shuttle Diagnostics, Inc., a wholly owned subsidiary of ShuttlePharma, focused on developing a diagnostics laboratory to develop its metabolite discovery platform technology and to perform multi-institutional clinical trials.\"We achieved a significant milestone in January 2024 with the receipt of the 'Safe to Proceed' letter from the U.S. Food and Drug Administration  to commence Ropidoxuridine's Phase 2 clinical trial,\" stated Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. \"We are currently finalizing site enrollment with 'first patient, first dose' expected in the second quarter of 2024. The r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6CgZRBPtk4hx1fXgU3oJVg--~B/aD0yNzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/435cbed05e34f2f008fa12b6ca316c59","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6CgZRBPtk4hx1fXgU3oJVg--~B/aD0yNzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/435cbed05e34f2f008fa12b6ca316c59"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/shuttle-pharma-provides-fourth-quarter-130000617.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharma-provides-fourth-quarter-130000617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2417582411","title":"Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2417582411","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2417582411?lang=en_us&edition=fundamental","pubTime":"2024-03-05 22:00","pubTimestamp":1709647200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., March 05, 2024  -- Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy , today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on March 6, 2024.Dr. Dritschilo’s presentation will be on Wednesday, March 6, 2024 at 11:25 am ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharmaceuticals-present-emerging-growth-140000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2411236596","title":"BRIEF-Shuttle Pharma Announces Its Intent To Pursue A Rights Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2411236596","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2411236596?lang=en_us&edition=fundamental","pubTime":"2024-02-13 23:20","pubTimestamp":1707837659,"startTime":"0","endTime":"0","summary":"Feb 13  - Shuttle Pharmaceuticals Holdings Inc :   * SHUTTLE PHARMA ANNOUNCES ITS INTENT TO PURSUE A RIGHTS OFFERING   * INTENT TO COMMENCE A RIGHTS OFFERING WHERE IT PLANS TO RAISE UP TO $4.5 MILLION THROUGH DISTRIBUTION OF SUBSCRIPTION RIGHTSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2411351545","title":"Shuttle Pharmaceuticals Advances Prostate Cancer Diagnostics Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2411351545","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2411351545?lang=en_us&edition=fundamental","pubTime":"2024-02-13 21:13","pubTimestamp":1707829992,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has released an update. Shuttle Pharmaceuticals Holdings, Inc. has entered into an agreement with SRO...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shuttle-pharmaceuticals-advances-prostate-cancer-diagnostics-funding?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shuttle-pharmaceuticals-advances-prostate-cancer-diagnostics-funding?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SHPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shuttlepharma.com","stockEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":-0.0528},{"period":"3month","weight":-0.0643},{"period":"6month","weight":-0.1458},{"period":"1year","weight":-0.6293},{"period":"ytd","weight":-0.1363}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":0.0291},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.1429},{"period":"1year","weight":0.2628},{"period":"ytd","weight":0.1463}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.","exchange":"NASDAQ","name":"Shuttle Pharmaceuticals Inc","nameEN":"Shuttle Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shuttle Pharmaceuticals Inc,SHPH,Shuttle Pharmaceuticals Inc股票,Shuttle Pharmaceuticals Inc股票老虎,Shuttle Pharmaceuticals Inc股票老虎国际,Shuttle Pharmaceuticals Inc行情,Shuttle Pharmaceuticals Inc股票行情,Shuttle Pharmaceuticals Inc股价,Shuttle Pharmaceuticals Inc股市,Shuttle Pharmaceuticals Inc股票价格,Shuttle Pharmaceuticals Inc股票交易,Shuttle Pharmaceuticals Inc股票购买,Shuttle Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction